Project description
Innovative technological solution to provide intelligent dosing in ADHD
Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioural disorder with a childhood-onset that combines lack of attention with hyperactivity, impairing multiple aspects of life. Stimulants are primary effective ADHD medications, classified as controlled substances associated with side effects and potential for abuse. They require dose titration throughout the patients’ life. The goal of the EU-funded OnDosis01 project is to develop a therapeutic device that allows effective management of ADHD. This technology will introduce a new way to deliver treatment, integrating medication self-monitoring with intelligent dosing. The integration will simplify dose titration, enabling adherence improvement and reducing risk for medication abuse via tamper resistance.
Objective
The goal of this project is to develop a therapy that allows for more effective management of attention-deficit hyperactivity disorder (ADHD). ADHD is a common, childhood onset, neurobehavioural disorder characterised by a combination of inattention, hyperactivity and impulsivity impairing multiple areas of life. Stimulants are the most widely used ADHD medications and are proven effective on ADHD symptoms, but classified as controlled substances they are associated with concerns about side effects and potential for abuse. In addition, they require careful dose titration at initiation and throughout the patients’ life.
OnDosis aims to address these challenges by developing a novel “combination product”, prescribed as an ADHD treatment regime, that combines a technological platform with stimulant active compounds. This integrated solution will simplify dose titration, enable ease of swallowing, offer adherence support and self-monitoring checks. Importantly, OnDosis’ solution is a personalised device with the potential to reduce risk for medication abuse through tamper resistance and tamper evident features.
The ultimate success of the project will depend on generation of clinical data which will support partnering and out-licensing. OnDosis plans to apply for SMEi Phase 2 grant to take the product through required clinical studies, and then go to market through a licensing agreement with a strong commercial partner. OnDosis has a strong network established with potential pharma partners and investors, and has already gained support from investors that offer strategic support to the company.
The burden of ADHD is increasing and the unmet need is growing. This encourages OnDosis in the endeavour of a needs-driven research to address this widespread challenge. Market research with several stakeholders in healthcare have convinced OnDosis of the potential to bring significant impact to patients with ADHD through this novel technology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine neurology epilepsy
- social sciences sociology demography mortality
- medical and health sciences clinical medicine psychiatry
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
431 50 MOLNDAL
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.